246 Infos zu Günter Fingerle-rowson

16 Aktuelle Nachrichten

vor 1 Tag — ... Günter Fingerle-Rowson, MD, PhD, Chief Medical Officer von Tubulis. Der von der FDA gewährte Fast-Track-Status soll die Entwicklung ...

— Tubulis today announced the appointment of Günter Fingerle-Rowson, MD, PhD, as Chief Medical Officer to complement the leadership team and — Tubulis today announced the appointment of Günter Fingerle-Rowson, MD, PhD, as Chief Medical Officer to complement the leadership team and ...

MUNICH, GERMANY, April 20, 2021– Tubulis, today announced the appointment of Günter Fingerle-Rowson, MD, PhD, as Chief Medical Officer to complement the leadership team and to further build the company’s clinical expertise. Dr. Fingerle-Rowson is an experienced

— “ Das Tubulis-Management-Team v.l.n.r.: CMO Dr. Günter Fingerle-Rowson, MD, CSO Dr. Jonas Helma-Smets, CEO Dr. Dominik Schumacher, CBO Dr — “ Das Tubulis-Management-Team v.l.n.r.: CMO Dr. Günter Fingerle-Rowson, MD, CSO Dr. Jonas Helma-Smets, CEO Dr. Dominik Schumacher, CBO Dr ...

9 Profile in Sozialen Netzwerken

Günter Fingerle-Rowson · Chief Medical Officer at Tubulis GmbH · Melden · Melden · Info · Aktivitäten · Berufserfahrung · Ausbildung · Weitere Aktivitäten von Günter ...

Paparan Günter Fingerle-Rowson. Lihat profil Günter Fingerle-Rowson · Günter Fingerle-Rowson. Chief Medical Officer at Tubulis GmbH.

Günter Fingerle-Rowson's Post. View profile for Günter Fingerle-Rowson · Günter Fingerle-Rowson. Chief Medical Officer at Tubulis GmbH.

Don't miss our CMO, Günter Fingerle-Rowson. @EORTC. 's CLTG meeting where he will present new data on our #lymphoma-targeting #ADC candidate TUB-010, based on ...

8 Hobbys & Interessen

B., Marek Trněný, M.D., Michael Wenger, M.D., Günter Fingerle-Rowson, M.D., Ph.D., Kaspar Rufibach, Ph.D., Tom Moore, M.B., Ch.B., Michael Herold, M.D., and ... B., Marek Trněný, M.D., Michael Wenger, M.D., Günter Fingerle-Rowson, M.D., Ph.D., Kaspar Rufibach, Ph.D., Tom Moore, M.B., Ch.B., Michael Herold, M.D., and ...

... Günter Fingerle-Rowson, MD, Prof Bruce D Cheson, MD. The Lancet Oncology. Volume 17 Issue 8 Pages (August 2016). DOI: S (16) Günter Fingerle-Rowson, MD, Prof Bruce D Cheson, MD. The Lancet Oncology. Volume 17 Issue 8 Pages (August 2016). DOI: S (16)

20. Apr · Tubulis today announced the appointment of Günter Fingerle-Rowson, MD, PhD, as Chief Medical Officer to complement the leadership team and to further.

... Günter Fingerle-Rowson, MD, Bruce D Cheson, ProfMD. a British Columbia Cancer Agency, Vancouver, BC, Canada. b University of British Columbia, Vancouver Günter Fingerle-Rowson, MD, Bruce D Cheson, ProfMD. a British Columbia Cancer Agency, Vancouver, BC, Canada. b University of British Columbia, Vancouver ...

3 Business-Profile

Günter Fingerle-Rowson, Basel Berufserfahrung, Kontaktdaten, Portfolio und weitere Infos: Erfahr mehr – oder kontaktier Günter Fingerle-Rowson direkt bei XING.

Günter Fingerle-Rowson CD74 is a surface protein expressed on immune cells, which acts as receptor for the chemokine macrophage migration inhibitory factor (MIF).

Günter Fingerle-Rowson. Unlabelled: Survival of chronic lymphocytic leukemia (CLL) cells depends on stimuli provided by a suitable ... Günter Fingerle-Rowson. Unlabelled: Survival of chronic lymphocytic leukemia (CLL) cells depends on stimuli provided by a suitable ...

1 Firmen-Mitarbeiter

About us · Team · Supervisory Board · Scientific Advisory Board · Technology · Pipeline · Investors · Career · News & Events · Contact us. About us · Team · Supervisory Board · Scientific Advisory Board · Technology · Pipeline · Investors · Career · News & Events · Contact us.

2 Persönliche Webseiten

To contact Günter Fingerle-Rowson send an email to or .

15 Bücher zum Namen

von A Nemajerova · · Zitiert von: 51 — ,. Ute M. Moll. ,. Oleksi Petrenko. &. Günter Fingerle-Rowson. Pages | Published online: 01 May Cite this article · https://doi.org cc. von A Nemajerova · · Zitiert von: 51 — ,. Ute M. Moll. ,. Oleksi Petrenko. &. Günter Fingerle-Rowson. Pages | Published online: 01 May Cite this article · https://doi.org cc.

... Günter Fingerle-Rowson, and Oliver W Press “Randomized Phase II Trial Comparing Obinutuzumab (GA101) with Rituximab in Patients with Relapsed CD20+ ...

Günter Fingerle-Rowson is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Obinutuzumab & Follicular ...

... Günter Fingerle-Rowson, and Pablo Umaña Introduction 245 Preclinical Experience with Obinutuzumab 246 Characteristics and Mechanisms of Action of Type I and ...

33 Dokumente

von O Al‐Sawaf · · Zitiert von: 7 — ... Günter Fingerle-Rowson,. Günter Fingerle-Rowson. F. Hoffmann-La Roche, Basel, Switzerland. Search for more papers by this author · Stephan ... von O Al‐Sawaf · · Zitiert von: 7 — ... Günter Fingerle-Rowson,. Günter Fingerle-Rowson. F. Hoffmann-La Roche, Basel, Switzerland. Search for more papers by this author · Stephan ...

— Tubulis appoints Günter Fingerle-Rowson as Chief Medical Officer to lead the clinical development of its new generation of ADCs. MUNICH ...

von C Klein · · Zitiert von: 1 — Günter Fingerle-Rowson,. Günter Fingerle-Rowson. Pharma Development Oncology, F. Hoffmann-La Roche, Basel, Switzerland. Search for more papers ... von C Klein · · Zitiert von: 1 — Günter Fingerle-Rowson,. Günter Fingerle-Rowson. Pharma Development Oncology, F. Hoffmann-La Roche, Basel, Switzerland. Search for more papers ...

von N Reinart · · Zitiert von: 115 — Günter Fingerle-Rowson. Günter Fingerle-Rowson. 1Department I of Internal Medicine, University Hospital Cologne, and Center for Integrated Oncology Köln-Bonn ... von N Reinart · · Zitiert von: 115 — Günter Fingerle-Rowson. Günter Fingerle-Rowson. 1Department I of Internal Medicine, University Hospital Cologne, and Center for Integrated Oncology Köln-Bonn ...

15 Wissenschaftliche Publikationen

Privatdozent Dr. Günter Fingerle-Rowson, Klinik für Innere Medizin IKöln. Privatdozent Dr. Günter Fingerle-Rowson, Klinik für Innere Medizin IKöln.

von G Fingerle-Rowson · · Zitiert von: 48 — MIF coordinates the cell cycle with DNA damage checkpoints. Lessons from knockout mouse models. Günter Fingerle-Rowson &; Oleksi Petrenko. Cell ... von G Fingerle-Rowson · · Zitiert von: 48 — MIF coordinates the cell cycle with DNA damage checkpoints. Lessons from knockout mouse models. Günter Fingerle-Rowson &; Oleksi Petrenko. Cell ...

von CR Bolen · · Zitiert von: 48 — ... Günter Fingerle-Rowson (3) , Tina Nielsen (3) , Georg Lenz (8) , Mikkel Z. Oestergaard (3). Afficher plus de détails. 1 Genentech, Inc. [San Francisco] von CR Bolen · · Zitiert von: 48 — ... Günter Fingerle-Rowson (3) , Tina Nielsen (3) , Georg Lenz (8) , Mikkel Z. Oestergaard (3). Afficher plus de détails. 1 Genentech, Inc. [San Francisco]

von V Goede · · Zitiert von: 11 — ... Guenter Fingerle-Rowson, MD PhD,5 Stephan Stilgenbauer, MD,6 Manuela A. Bergmann, MD,7 Barbara F. Eichhorst, MD,8 Michael Hallek8,9 1Department I of ... von V Goede · · Zitiert von: 11 — ... Guenter Fingerle-Rowson, MD PhD,5 Stephan Stilgenbauer, MD,6 Manuela A. Bergmann, MD,7 Barbara F. Eichhorst, MD,8 Michael Hallek8,9 1Department I of ...

8 Allgemeine Veröffentlichungen

von K Tobinai · · Zitiert von: 174 — Günter Fingerle-Rowson is an employee at F. Hoffmann-La Roche Ltd. and owns stock in F. Hoffmann-La Roche Ltd. Compliance with Ethics ... von K Tobinai · · Zitiert von: 174 — Günter Fingerle-Rowson is an employee at F. Hoffmann-La Roche Ltd. and owns stock in F. Hoffmann-La Roche Ltd. Compliance with Ethics ...

Günter Fingerle-Rowson. The cost-effectiveness of rituximab in combination with fludarabine/cyclophosphamide (R-FC) for the first line ... Günter Fingerle-Rowson. The cost-effectiveness of rituximab in combination with fludarabine/cyclophosphamide (R-FC) for the first line ...

von G Fingerle-Rowson · · Zitiert von: 110 — Authors and Affiliations. Department of Internal Medicine I, Klinikum Grosshadern, University of Muenchen, Muenchen, FRG. Günter Fingerle-Rowson & Jens Auers. von G Fingerle-Rowson · · Zitiert von: 110 — Authors and Affiliations. Department of Internal Medicine I, Klinikum Grosshadern, University of Muenchen, Muenchen, FRG. Günter Fingerle-Rowson & Jens Auers.

— Günter Fingerle-Rowson. Introduction: Obinutuzumab is a novel humanized type II glycoengineered anti-CD20 antibody — Günter Fingerle-Rowson. Introduction: Obinutuzumab is a novel humanized type II glycoengineered anti-CD20 antibody ...

3 Video- & Audioinhalte

— Günter Fingerle-Rowson, MD, CMO; Dr. Jonas Helma-Smets, CSO; Dr. Dominik Schumacher, CEO; Dr. Ingo Lehrke, CBO; Dr. Björn Hock, CDO ...

— Günter Fingerle-Rowson, Chief Medical Officer bei Tubulis. "Die neuartige P5-Technologie, die wir in TUB-040 verwenden, verbessert die — Günter Fingerle-Rowson, Chief Medical Officer bei Tubulis. "Die neuartige P5-Technologie, die wir in TUB-040 verwenden, verbessert die ...

— Günter Fingerle-Rowson, MD (CMO), Dr. Jonas Helma-Smets (CSO), Dr. Dominik Schumacher (CEO, Member of the Supervisory Board), Dr. Ingo — Günter Fingerle-Rowson, MD (CMO), Dr. Jonas Helma-Smets (CSO), Dr. Dominik Schumacher (CEO, Member of the Supervisory Board), Dr. Ingo ...

5 Meinungen & Artikel

— ... Günter Fingerle-Rowson, MD, PhD, Chief Medical Officer at Tubulis. "The novel P5 technology we use in TUB-040 improves upon current ...

vor 3 Tagen — ... Günter Fingerle-Rowson, MD, PhD, Chief Medical Officer at Tubulis. “Initiating our first clinical trial represents an important milestone ... vor 3 Tagen — ... Günter Fingerle-Rowson, MD, PhD, Chief Medical Officer at Tubulis. “Initiating our first clinical trial represents an important milestone ...

— Günter Fingerle-Rowson, MD (CMO), Dr. Jonas Helma-Smets (CSO), Dr. Dominik Schumacher (CEO, Mitglied des Aufsichtsrates), Dr. Ingo Lehrke (CBO) — Günter Fingerle-Rowson, MD (CMO), Dr. Jonas Helma-Smets (CSO), Dr. Dominik Schumacher (CEO, Mitglied des Aufsichtsrates), Dr. Ingo Lehrke (CBO) ...

von C Pott · · Zitiert von: 19 — Nathalie Spielewoy, Guenter Fingerle-Rowson, Kirsten Mundt & Elisabeth Wassner-Fritsch. Roche, Welwyn Garden City, UK. Chris Harbron.

125 Webfunde aus dem Netz

vor 2 Tagen — ... Günter Fingerle-Rowson, MD, PhD, Chief Medical Officer of Tubulis. "The FDA decision brings us one step closer to our goal of delivering the ... vor 2 Tagen — ... Günter Fingerle-Rowson, MD, PhD, Chief Medical Officer of Tubulis. "The FDA decision brings us one step closer to our goal of delivering the ...

Guenter Fingerle-Rowson. Pharma Development, F. Hoffmann-La Roche Ltd. ( Basel, Switzerland). Odborné práce publikované na Linkos.cz. Přehled odborných textů ... Guenter Fingerle-Rowson. Pharma Development, F. Hoffmann-La Roche Ltd. ( Basel, Switzerland). Odborné práce publikované na Linkos.cz. Přehled odborných textů ...

The groups of Associate Professor Günter Fingerle-Rowson and Dr Marco Herling work on the identification of new oncogenic signal transduction pathways in CLL ...

Günter Fingerle-Rowson is the current CMO at Tubulis. Günter has also previously worked as an Associate Group Medical Director, Global Development Team ...

See what Günter Fingerle-Rowson (fingerlerowson) has discovered on Pinterest, the world's biggest collection of ideas. See what Günter Fingerle-Rowson (fingerlerowson) has discovered on Pinterest, the world's biggest collection of ideas.

Günter Fingerle-Rowson. fingerlerowson. ·. フォロワー：0 人. ·. フォロー中：0 人. フォロー. fingerlerowson さんはまだピンを保存していません.

Günter Fingerle-Rowson · この人物について · 関連論文 · 関連研究データ · 関連図書・雑誌 · 関連博士論文 · 関連プロジェクト · 関連その他成果物 · 詳細情報.

Guenter Fingerle-Rowson · · Personal information · Activities. Guenter Fingerle-Rowson · · Personal information · Activities.

von C Pott · · Zitiert von: 30 — ... Guenter Fingerle-Rowson, F. Hoffmann-La Roche Ltd · Chris Harbron, Roche · Kirsten Mundt, F. Hoffmann-La Roche Ltd · Elisabeth Wassner-Fritsch, ... von C Pott · · Zitiert von: 30 — ... Guenter Fingerle-Rowson, F. Hoffmann-La Roche Ltd · Chris Harbron, Roche · Kirsten Mundt, F. Hoffmann-La Roche Ltd · Elisabeth Wassner-Fritsch, ...

... Günter Fingerle-Rowson, Dr. Jonas Helma-Smets, Dr. Dominik Schumacher, Dr. Ingo Lehrke und Dr. Björn Hock. © Tubulis März 24. BioTech-Innovation im Günter Fingerle-Rowson, Dr. Jonas Helma-Smets, Dr. Dominik Schumacher, Dr. Ingo Lehrke und Dr. Björn Hock. © Tubulis März 24. BioTech-Innovation im ...

Günter Fingerle-Rowson,. Günter Fingerle-Rowson. 2F. Hoffmann-La Roche Ltd, Basel, Switzerland;. Search for other works by this author on: This Site · PubMed.

vor 17 Stunden — ... Günter Fingerle-Rowson, MD, PhD, chief medical officer of Tubulis, in a press release. "The FDA decision brings us one step closer to our ... vor 17 Stunden — ... Günter Fingerle-Rowson, MD, PhD, chief medical officer of Tubulis, in a press release. "The FDA decision brings us one step closer to our ...

vor 1 Tag — ... Günter Fingerle-Rowson, MD, PhD, chief medical officer of Tubulis, in a press release. "The FDA decision brings us one step closer to our ... vor 1 Tag — ... Günter Fingerle-Rowson, MD, PhD, chief medical officer of Tubulis, in a press release. "The FDA decision brings us one step closer to our ...

Paulson, Eugene Kim, Umberto Vitolo, Alice Di Rocco, Günter Fingerle-Rowson, Tina Nielsen, Georg Lenz and Mikkel Z. Oestergaard (2019) “Prognostic impact of ... Paulson, Eugene Kim, Umberto Vitolo, Alice Di Rocco, Günter Fingerle-Rowson, Tina Nielsen, Georg Lenz and Mikkel Z. Oestergaard (2019) “Prognostic impact of ...

... Guenter Fingerle-Rowson, Claude Berge, Deniz Sahin, Oliver Press, Laurie Sehn. Department of Translational Medicine. Research output: Contribution to journal Guenter Fingerle-Rowson, Claude Berge, Deniz Sahin, Oliver Press, Laurie Sehn. Department of Translational Medicine. Research output: Contribution to journal ...

von W Hiddemann · · Zitiert von: 220 — ... Günter Fingerle-rowson, Marcel Wolbers, Tina Nielsen, Robert E. Marcus. Division of Cancer Sciences (L5). Research output: Contribution to journal › Article ... von W Hiddemann · · Zitiert von: 220 — ... Günter Fingerle-rowson, Marcel Wolbers, Tina Nielsen, Robert E. Marcus. Division of Cancer Sciences (L5). Research output: Contribution to journal › Article ...

Niannian Ji, Andra Kovalovsky, Günter Fingerle-Rowson, M. Neal Guentzel, and Thomas G. Forsthuber. Macrophage migration inhibitory factor promotes ... Niannian Ji, Andra Kovalovsky, Günter Fingerle-Rowson, M. Neal Guentzel, and Thomas G. Forsthuber. Macrophage migration inhibitory factor promotes ...

... Guenter Fingerle-Rowson, Claude Berge, Deniz Sahin, Oliver Press, Laurie Sehn. Department of Translational Medicine. Research output: Contribution to journal ...

Günter Fingerle-Rowson. Employment: Roche. Stock or Other Ownership: Roche. Marcel Wolbers. Employment: Roche. Consulting or Advisory Role: Roche. Tina Nielsen.

... Guenter Fingerle-Rowson, Chris Harbron, Kirsten Mundt, Elisabeth Wassner-Fritsch, Bruce D. Cheson. Section of Medical Oncology · Siteman Cancer Center. Research Guenter Fingerle-Rowson, Chris Harbron, Kirsten Mundt, Elisabeth Wassner-Fritsch, Bruce D. Cheson. Section of Medical Oncology · Siteman Cancer Center. Research ...